Bio-Rad Laboratories and Myriad RBM have partnered to develop and distribute immunoassay kits. The agreement combines Myriad RBM’s menu of multiplexed immunoassays with Bio-Rad’s global commercial distribution capabilities. For research purposes, Myriad RBM grants Bio-Rad exclusive distribution rights to a catalog of quantitative multiplexed immunoassays currently available to run on the Bio-Plex® 200, Bio-Plex® 3D, and Bio-Plex® MAGPIX™ instruments.
In an effort to optimize treatment and improve patient care, the partnership allows Bio-Rad and Myriad RBM to help researchers and clinicians develop biomarker profiles that may predict, detect, or monitor disease progression. Researchers’ needs for multiplex testing of samples with very low volumes when studying toxicology, oncology, immunology, cardiovascular, and other diseases are addressed by Myriad RBM’s assays. The new assays expand Bio-Rad’s current suite of assays.